Book contents
- Movement Disorders and Inherited Metabolic Disorders
- Movement Disorders and Inherited Metabolic Disorders
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Acknowledgments
- Section I General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Section II A Metabolism-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Chapter 12 Disorders of Amino Acid Metabolism: Amino Acid Disorders, Organic Acidurias, and Urea Cycle Disorders with Movement Disorders
- Chapter 13 Disorders of Energy Metabolism: GLUT1 Deficiency Syndrome and Movement Disorders
- Chapter 14 Lysosomal Storage Disorders: Niemann–Pick Disease Type C and Movement Disorders
- Chapter 15 Lysosomal Storage Disorders: Neuronal Ceroid Lipofuscinoses and Movement Disorders
- Chapter 16 Syndromes of Neurodegeneration with Brain Iron Accumulation
- Chapter 17 Metal Storage Disorders: Inherited Disorders of Copper and Manganese Metabolism and Movement Disorders
- Chapter 18 Metal Storage Disorders: Primary Familial Brain Calcification and Movement Disorders
- Chapter 19 Disorders of Glycosylation and Movement Disorders
- Chapter 20 Disorders of Post-Translational Modifications/Degradation: Autophagy and Movement Disorders
- Chapter 21 Neurotransmitter Disorders: Disorders of Dopamine Metabolism and Movement Disorders
- Chapter 22 Neurotransmitter Disorders: DNAJC12-Deficient Hyperphenylalaninemia – An Emerging Neurotransmitter Disorder
- Chapter 23 Neurotransmitter Disorders: Disorders of GABA Metabolism and Movement Disorders
- Chapter 24 Vitamin-Responsive Disorders: Ataxia with Vitamin E Deficiency and Movement Disorders
- Chapter 25 Vitamin-Responsive Disorders: Biotin–Thiamine-Responsive Basal Ganglia Disease and Movement Disorders
- Chapter 26 Disorders of Cholesterol Metabolism: Cerebrotendinous Xanthomatosis and Movement Disorders
- Chapter 27 Purine Metabolism Defects: The Movement Disorder of Lesch–Nyhan Disease
- Chapter 28 Disorders of Creatine Metabolism: Creatine Deficiency Syndromes and Movement Disorders
- Chapter 29 Hereditary Spastic Paraplegia-Related Inborn Errors of Metabolism
- Section III Conclusions and Future Directions
- Appendix: Video Captions
- Index
- References
Chapter 27 - Purine Metabolism Defects: The Movement Disorder of Lesch–Nyhan Disease
from Section II - A Metabolism-Based Approach to Movement Disorders and Inherited Metabolic Disorders
Published online by Cambridge University Press: 24 September 2020
Book contents
- Movement Disorders and Inherited Metabolic Disorders
- Movement Disorders and Inherited Metabolic Disorders
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Acknowledgments
- Section I General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Section II A Metabolism-Based Approach to Movement Disorders and Inherited Metabolic Disorders
- Chapter 12 Disorders of Amino Acid Metabolism: Amino Acid Disorders, Organic Acidurias, and Urea Cycle Disorders with Movement Disorders
- Chapter 13 Disorders of Energy Metabolism: GLUT1 Deficiency Syndrome and Movement Disorders
- Chapter 14 Lysosomal Storage Disorders: Niemann–Pick Disease Type C and Movement Disorders
- Chapter 15 Lysosomal Storage Disorders: Neuronal Ceroid Lipofuscinoses and Movement Disorders
- Chapter 16 Syndromes of Neurodegeneration with Brain Iron Accumulation
- Chapter 17 Metal Storage Disorders: Inherited Disorders of Copper and Manganese Metabolism and Movement Disorders
- Chapter 18 Metal Storage Disorders: Primary Familial Brain Calcification and Movement Disorders
- Chapter 19 Disorders of Glycosylation and Movement Disorders
- Chapter 20 Disorders of Post-Translational Modifications/Degradation: Autophagy and Movement Disorders
- Chapter 21 Neurotransmitter Disorders: Disorders of Dopamine Metabolism and Movement Disorders
- Chapter 22 Neurotransmitter Disorders: DNAJC12-Deficient Hyperphenylalaninemia – An Emerging Neurotransmitter Disorder
- Chapter 23 Neurotransmitter Disorders: Disorders of GABA Metabolism and Movement Disorders
- Chapter 24 Vitamin-Responsive Disorders: Ataxia with Vitamin E Deficiency and Movement Disorders
- Chapter 25 Vitamin-Responsive Disorders: Biotin–Thiamine-Responsive Basal Ganglia Disease and Movement Disorders
- Chapter 26 Disorders of Cholesterol Metabolism: Cerebrotendinous Xanthomatosis and Movement Disorders
- Chapter 27 Purine Metabolism Defects: The Movement Disorder of Lesch–Nyhan Disease
- Chapter 28 Disorders of Creatine Metabolism: Creatine Deficiency Syndromes and Movement Disorders
- Chapter 29 Hereditary Spastic Paraplegia-Related Inborn Errors of Metabolism
- Section III Conclusions and Future Directions
- Appendix: Video Captions
- Index
- References
Summary
Purine metabolism encompasses the metabolic pathways involved in the synthesis, interconversion, salvage, and degradation of purine-based nucleosides and nucleotides. These metabolic pathways are involved in many essential cellular processes, including energy transfer, oxidative phosphorylation, synthesis of DNA and RNA, and signal transduction. A nucleoside is a nitrogenous base linked to a 5-carbon sugar (either ribose or deoxyribose). For purines, this nitrogenous base is either adenine, guanine, or hypoxanthine. When nucleosides are covalently linked to one or more phosphate groups, they are referred to as nucleotides.
- Type
- Chapter
- Information
- Movement Disorders and Inherited Metabolic DisordersRecognition, Understanding, Improving Outcomes, pp. 327 - 341Publisher: Cambridge University PressPrint publication year: 2020
References
Gacasan, SB, Baker, DL, Parrill, AL. G protein-coupled receptors: The evolution of structural insight. AIMS Biophys. 2017;4(3):491–527.Google Scholar
Harris, JJ, Attwell, D. The energetics of CNS white matter. J Neurosci. 2012;32(1):356–71.CrossRefGoogle ScholarPubMed
Attwell, D, Laughlin, SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21(10):1133–45.Google Scholar
Abbracchio, MP, Burnstock, G, Verkhratsky, A, Zimmermann, H. Purinergic signalling in the nervous system: An overview. Trends Neurosci. 2009;32(1):19–29.Google Scholar
Camici, M, Micheli, V, Ipata, PL, Tozzi, MG. Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem Int. 2010;56(3):367–78.Google Scholar
Kamatani, N, Jinnah, HA, Hennekam, FA, Van Kuilenburg, ABP. Purine and pyrimidine metabolism. In Rimoin, DL, Pyeritz, RE, Korf, BR, editors. Principles and Practice of Medical Genetics. San Diego, CA: Academic Press; 2013, pp. 1–38.Google Scholar
Jinnah, HA, Sabina, RL, Van Den Berghe, G. Metabolic disorders of purine metabolism affecting the nervous system. Handb Clin Neurol. 2013;113:1827–36.Google Scholar
de Brouwer, AP, van Bokhoven, H, Nabuurs, SB, et al. PRPS1 mutations: Four distinct syndromes and potential treatment. Am J Hum Genet. 2010;86(4):506–18.Google Scholar
Baresova, V, Skopova, V, Sikora, J, et al. Mutations of ATIC and ADSL affect purinosome assembly in cultured skin fibroblasts from patients with AICA-ribosiduria and ADSL deficiency. Hum Mol Genet. 2012;21(7):1534–43.Google Scholar
Morisaki, T, Gross, M, Morisaki, H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA. 1992;89(14):6457–61.Google Scholar
Sabine, RL, Holmes, EW. Myoadenylate deaminase deficiency. In Scriver, CR, Beaudet, AL, Sly, WS, Valle, D, editors. The Metabolic and Molecular Basis of Inherited Disease. II. New York, NY: McGraw-Hill; 2001, pp. 2627–38.Google Scholar
Torres, RJ, Puig, JG, Jinnah, HA. Update on the phenotypic spectrum of Lesch–Nyhan disease and its attenuated variants. Curr Rheumatol Rep. 2012;14(2):189–94.Google Scholar
Jinnah, HA, Ceballos-Picot, I, Torres, RJ, et al. Attenuated variants of Lesch–Nyhan disease. Brain. 2010;133(Pt 3):671–89.Google Scholar
Jinnah, HA, Visser, JE, Harris, JC, et al. Delineation of the motor disorder of Lesch–Nyhan disease. Brain. 2006;129(Pt 5):1201–17.Google Scholar
Watts, RW, Spellacy, E, Gibbs, DA, et al. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch–Nyhan syndrome with particular reference to the neurological manifestations. Q J Med. 1982;51(201):43–78.Google Scholar
Matthews, WS, Solan, A, Barabas, G. Cognitive functioning in Lesch–Nyhan syndrome. Dev Med Child Neurol. 1995;37(8):715–22.Google Scholar
Schretlen, DJ, Harris, JC, Park, KS, Jinnah, HA, del Pozo, NO. Neurocognitive functioning in Lesch–Nyhan disease and partial hypoxanthine–guanine phosphoribosyltransferase deficiency. J Int Neuropsychol Soc. 2001;7(7):805–12.Google Scholar
Anderson, LT, Ernst, M. Self-injury in Lesch–Nyhan disease. J Autism Dev Disord. 1994;24(1):67–81.Google Scholar
Nyhan, WL. Behavior in the Lesch–Nyhan syndrome. J Autism Child Schizophr. 1976;6(3):235–52.Google Scholar
Jolly, DJ, Okayama, H, Berg, P, et al. Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyl transferase. Proc Natl Acad Sci USA. 1983;80(2):477–81.Google Scholar
Fu, R, Ceballos-Picot, I, Torres, RJ, et al. Genotype–phenotype correlations in neurogenetics: Lesch–Nyhan disease as a model disorder. Brain. 2014;137(Pt 5):1282–303.CrossRefGoogle ScholarPubMed
Jinnah, HA, De Gregorio, L, Harris, JC, Nyhan, WL, O’Neill, JP. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res. 2000;463(3):309–26.Google Scholar
Harris, JC, Lee, RR, Jinnah, HA, et al. Craniocerebral magnetic resonance imaging measurement and findings in Lesch–Nyhan syndrome. Arch Neurol. 1998;55(4):547–53.Google Scholar
Schretlen, DJ, Varvaris, M, Ho, TE, et al. Regional brain volume abnormalities in Lesch–Nyhan disease and its variants: A cross-sectional study. Lancet Neurol. 2013;12(12):1151–8.CrossRefGoogle ScholarPubMed
Schretlen, DJ, Varvaris, M, Vannorsdall, TD, et al. Brain white matter volume abnormalities in Lesch–Nyhan disease and its variants. Neurology. 2015;84(2):190–6.Google Scholar
Gottle, M, Prudente, CN, Fu, R, et al. Loss of dopamine phenotype among midbrain neurons in Lesch–Nyhan disease. Ann Neurol. 2014;76(1):95–107.Google Scholar
Lloyd, KG, Hornykiewicz, O, Davidson, L, et al. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch–Nyhan syndrome. N Engl J Med. 1981;305(19):1106–11.Google Scholar
Saito, Y, Ito, M, Hanaoka, S, et al. Dopamine receptor upregulation in Lesch–Nyhan syndrome: A postmortem study. Neuropediatrics. 1999;30(2):66–71.Google Scholar
Ernst, M, Zametkin, AJ, Matochik, JA, et al. Presynaptic dopaminergic deficits in Lesch–Nyhan disease. N Engl J Med. 1996;334(24):1568–72.Google Scholar
Wong, DF, Harris, JC, Naidu, S, et al. Dopamine transporters are markedly reduced in Lesch–Nyhan disease in vivo. Proc Natl Acad Sci USA. 1996;93(11):5539–43.CrossRefGoogle ScholarPubMed
Jinnah, HA, Wojcik, BE, Hunt, M, et al. Dopamine deficiency in a genetic mouse model of Lesch–Nyhan disease. J Neurosci. 1994; 14 (3 Pt 1): 1164–75.Google Scholar
Ceballos-Picot, I, Mockel, L, Potier, MC, et al. Hypoxanthine–guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: Implications for Lesch–Nyhan disease pathogenesis. Hum Mol Genet. 2009;18(13):2317–27.CrossRefGoogle ScholarPubMed
Guibinga, GH, Hsu, S, Friedmann, T. Deficiency of the housekeeping gene hypoxanthine–guanine phosphoribosyltransferase (HPRT) dysregulates neurogenesis. Mol Ther. 2010;18(1):54–62.CrossRefGoogle ScholarPubMed
Kang, TH, Guibinga, GH, Jinnah, HA, Friedmann, T. HPRT deficiency coordinately dysregulates canonical Wnt and presenilin-1 signaling: A neuro-developmental regulatory role for a housekeeping gene? PLoS One. 2011;6(1):e16572.Google Scholar
Hyland, K, Kasim, S, Egami, K, Arnold, LA, Jinnah, HA. Tetrahydrobiopterin deficiency and dopamine loss in a genetic mouse model of Lesch–Nyhan disease. J Inherit Metab Dis. 2004;27(2):165–78.Google Scholar
Visser, JE, Bar, PR, Jinnah, HA. Lesch–Nyhan disease and the basal ganglia. Brain Res Brain Res Rev. 2000; 32 (2–3): 449–75.Google Scholar
Visser, JE, Smith, DW, Moy, SS, et al. Oxidative stress and dopamine deficiency in a genetic mouse model of Lesch–Nyhan disease. Brain Res Dev Brain Res. 2002;133(2):127–39.Google Scholar
Alexander, GE, Crutcher, MD, DeLong, MR. Basal ganglia–thalamocortical circuits: Parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Prog Brain Res. 1990;85:119–46.Google Scholar
Ng, J, Papandreou, A, Heales, SJ, Kurian, MA. Monoamine neurotransmitter disorders: Clinical advances and future perspectives. Nat Rev Neurol. 2015;11(10):567–84.Google Scholar
Wijemanne, S, Jankovic, J. Dopa-responsive dystonia: Clinical and genetic heterogeneity. Nat Rev Neurol. 2015;11(7):414–24.Google Scholar
Moy, SS, Criswell, HE, Breese, GR. Differential effects of bilateral dopamine depletion in neonatal and adult rats. Neurosci Biobehav Rev. 1997;21(4):425–35.Google Scholar
Crawhall, JC, Henderson, JF, Kelley, WN. Diagnosis and treatment of the Lesch–Nyhan syndrome. Pediatr Res. 1972;6(5):504–13.Google Scholar
Torres, RJ, Puig, JG. Hypoxanthine–guanine phosophoribosyltransferase (HPRT) deficiency: Lesch–Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48.CrossRefGoogle ScholarPubMed
Cotton, AC, Bell, RB, Jinnah, HA. Expert opinion vs patient perspective in treatment of rare disorders: Tooth removal in Lesch–Nyhan disease as an example. JIMD Rep. 2018;41:25–7.Google Scholar
Goodman, EM, Torres, RJ, Puig, JG, Jinnah, HA. Consequences of delayed dental extraction in Lesch–Nyhan disease. Mov Disord Clin Pract. 2014;1(3):225–9.Google Scholar